ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Kohlbrenner, Katharina; Galuschek, Norbert; Fabarius, Alice; Reiser, Marcel; Fenchel, Klaus; Esseling, Eva; Göhler, Thomas; Kühn, Ralf-Bodo; Depenbusch, Reinhard; Talah Azeh, Ivo; Engel, Erik; Hansen, Richard; Hanel, Mathias; Jehner, Paul; Abu-Samra, Maisun; Ritter, Markus; Gattermann, Norbert; Pelz, Henning; Fuxius, Stefan; Oswald, Burkhard; Baerlocher, Gabriela M; Brümmendorf, Tim H.; Heim, Dominik; le Coutre, Philipp; Burchert, Andreas; Niederwieser, Dietger; Tesch, Hans; Hofmann, Wolf-Karsten; Hochhaus, Andreas; Hehlmann, Rüdiger; Saussele, Susanne

doi:10.1182/blood-2023-180730

ELN Treatment Milestones in Chronic Myeloid Leukemia Are Prognostic for Achieving Deep Molecular Response and Treatment-Free Remission in Routine Care: Results of the German CML Registry

Introduction: Tyrosine kinase inhibitor (TKI) induced molecular response (MR) within the first months after diagnosis of chronic myeloid leukemia (CML) is critical for long-term outcome prediction. Aim: To analyze the prognostic relevance of MR according to European Leukemia Net (ELN) treatment m…